Semaglutide

What Is Semaglutide?

Semaglutide is a synthetic long-acting analogue of human glucagon-like peptide-1 (GLP-1), engineered with fatty-acid modification for extended plasma half-life. CertaPeptides supplies semaglutide for laboratory research in two formats: lyophilized powder (for injectable research protocols) and oral tablet form (3mg and 7mg). The oral tablet format is supplied as a research compound for comparative bioavailability and formulation studies only. This is not the pharmaceutical product Rybelsus (Novo Nordisk) and is not approved for human therapeutic use.

CAS: 910463-68-2. Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉. Molecular weight: 4113.58 g/mol.

Mechanism and Research Context

Semaglutide acts as an agonist at the GLP-1 receptor, a class B G-protein-coupled receptor. In receptor-binding assays and cell-based models it engages GLP-1R signalling (cAMP accumulation and downstream pathways). Its fatty-acid (C-18 diacid) modification mediates albumin binding and extends its plasma half-life relative to native GLP-1, which is why it is widely used as a long-acting reference agonist in incretin pharmacology research. It has been investigated in preclinical and in-vitro studies of GLP-1R pharmacology and rodent metabolic models (glucose homeostasis, insulin secretion, energy expenditure); these are reported here for research context only.

Within the Incretin Class — How Semaglutide Differs

Semaglutide is studied alongside two other research peptides in the same metabolic class: tirzepatide (dual GIP/GLP-1R agonist) and retatrutide (triple GIP/GLP-1/GCG agonist). The three differ structurally and mechanistically in ways that shape how each compound is studied:

Semaglutide's distinguishing features as a research tool are: (1) one of the most extensively characterised receptor-pharmacology profiles in the GLP-1 class; (2) the only research compound in the class supplied in both injectable and oral tablet form, enabling comparative bioavailability and formulation studies (see peptide bioavailability across administration routes); and (3) a frequently used reference compound in class comparisons — most newer incretin peptides are benchmarked against semaglutide. Researchers working across the class frequently reference the GLP-1 class comparison overview and the semaglutide mechanism-of-action research summary.

Research Areas Where Semaglutide Is Studied

• GLP-1 receptor pharmacology and in vitro receptor-binding assays
• Preclinical metabolic models (rodent glucose homeostasis, energy expenditure)
• Comparative studies vs dual/triple agonists (tirzepatide, retatrutide) in research settings
• Peptide stability and formulation research (oral vs injectable routes)

Specifications

Storage

Lyophilized powder: −20°C for long-term storage. 2–8°C for short-term use.

Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.

Oral tablets (3mg/7mg): Room temperature, dry, sealed. Keep away from light.

Quality Assurance

• Shipped to a ≥98% supplier batch specification
• Selected lots are independently tested by Janoshik Analytical (HPLC + mass spectrometry; 99.3% average purity across published reports)
• Independent reports searchable by batch code at certapeptides.com/verify
• EU-based quality control under CERTALAB S.R.L.

Important Notice — Research Use Only

Semaglutide is supplied by CertaPeptides strictly as a laboratory research compound. This product is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for over-the-counter sale for human or veterinary use. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.